Continued Benefit, More Toxicity With Osimertinib-Chemo

Source link :

The combination of osimertinib (Tagrisso, AstraZenca) plus chemotherapy is associated with continued benefits in previously untreated advanced EGFR-mutated non–small-cell lung cancer (NSCLC) even after disease progression, according to a postprogression analysis of the FLAURA2 trial. The results, presented on March 21 at the European Lung Cancer Congress 2024 (Abstract4O), also suggest a potential overall survival […]

Author : News Health

Publish date : 2024-03-25 17:39:30

Copyright for syndicated content belongs to the linked Source.